Niall O'Donnell

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA.

Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri.